1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. Hemostemix Inc (PK) (HMTXF)
  7. Quote


Hemostemix (PK) Stock Price

0.00 (0.0%)
Volume 0.00
Bid Price 0.12
Ask Price 0.1925
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Hemostemix Inc (PK) HMTXF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.16 07:33:36
Open Price Low Price High Price Close Price Prev Close
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.16 USD


Draw Mode:

Hemostemix Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 9.21M 57.57M 45.67M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
500.00 $ - - - -

more financials information »

Hemostemix (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HMTXF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1570.160.14850.1554714,4330.0031.91%
1 Month0.15930.1650.14640.154835618,0400.00070.44%
3 Months0.17620.19970.14640.164259210,617-0.0162-9.19%
6 Months0.26960.300.14640.221354513,303-0.1096-40.65%
1 Year0.00770.43720.00510.038077288,6150.15231,977.92%
3 Years0.0640.43720.00490.041724280,3330.096150.0%
5 Years0.03190.43720.00490.043810169,0090.1281401.57%

Hemostemix (PK) Description

Hemostemix is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat a variety of ischemic diseases with high, unmet medical needs, including critical limb ischemia and cardiovascular conditions. Hemostemix's proprietary platform technology is based on more than 10 years of clinical data demonstrating the ability of our autologous cell product to regenerate diseased and damaged tissue. ACP-01, our lead clinical stage candidate, is currently in a Phase II clinical trial for critical limb ischemia in Canada and the United States.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.